loading...| Preferred Name |
levocetirizine dihydrochloride |
|
| Synonyms |
Xyzal |
|
| Definitions |
The dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. In addition, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66008" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66008" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000742652 |
|
| altLabel |
Xyzal |
|
| CAS Registry |
130018-77-8 |
|
| cui |
C1311681 C1321643 |
|
| DATE FIRST PUBLISHED |
2012-11-09 |
|
| Date last modified |
2012-11-09 |
|
| definition |
The dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. In addition, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66008" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66008" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C66008 |
|
| notation |
CDR0000742652 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
levocetirizine dihydrochloride |
|
| tui |
T109 T121 |